Unicycive's annual report warned only that the FDA "could ask us to supplement our submissions," while a securities class action alleges the Company never disclosed that it had not inspected the third-party manufacturer whose unresolved cGMP deficiencies triggered a second Complete Response Letter and a 39.1% single-day loss for UNCY shareholders.